RNS Number:5111D
Hikma Pharmaceuticals Plc
07 September 2007





                   Notification of transaction by a Director


LONDON, 7 September 2006 - Hikma Pharmaceuticals PLC (the "Company") (LSE: HIK)
(DIFX:HIK) announces that Mr. Samih Darwazah, Non-executive Chairman of the
Company, has today notified the Company of the transfer of his entire direct
holding of 632,000 ordinary shares of 10 pence each in the capital of the
Company, to HMS Holding SAL, a company 99.66 percent owned by him. The remaining
outstanding shares of HMS Holding SAL are held equally between Mr. Darwazah's
wife, and his son, Mazen Darwazah. The transfer was made for nil consideration
and was made on 6 September 2006.

The shares transferred represent 0.374 per cent. of the issued ordinary shares
of 10 pence each in the capital of the Company, and following the notification
Mr. Darwazah no longer has a direct holding in the Company's ordinary shares.

Mr. Darwazah is both a director and a Person Discharging Managerial
Responsibility in respect of the Company, and the above notification relates
both to DR 3.1.4R(1)(a) and section 324 (as extended by section 328) of the
Companies Act 1985.


                                   -- ENDS --




Enquiries:

Hikma Pharmaceuticals PLC
Henry Knowles                                    +44 20 7399 2760
Company Secretary
Susan Ringdal                                    +44 20 7399 2760
Investor Relations Director


Brunswick Group
Jon Coles / Justine McIlroy / Alex Tweed         +44 20 7404 5959



About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products.  Hikma's operations
are conducted through three businesses: "Branded", "Injectables" and "Generics".
Hikma's operations are based principally in the Middle East and North Africa
("MENA") region, where it is a market leader and sells across 17 countries, the
United States and Europe.  In 2006, the Group achieved revenues of $317 million
(2005 $262 million) and profit attributable to shareholders was $55 million
(2005 $44 million).  At 30 June 2007, the Group had over 2,700 employees.  For
news and other information, please visit www.hikma.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

RDSMGGGLDNRGNZM
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Hikma Pharmaceuticals Charts.